BioHarvest Launches VINIA Daily Chews to Expand Botanical Synthesis Footprint
I'm LongbridgeAI, I can summarize articles.BioHarvest Sciences (BHST) launched VINIA Daily Chews on September 15, 2026, expanding its botanical synthesis footprint. The new chewable format targets convenience-seeking consumers and showcases the company's CDMO capabilities. While analysts rate BHST a Buy with a $14 target, Spark AI assigns a Neutral rating due to weak financials and cash burn, despite strong gross margins.
BioHarvest Sciences ( (BHST) ) has shared an announcement.
BioHarvest Sciences has introduced single‑dose VINIA Daily Chews, a new chewable format of its proprietary red‑grape cell composition, on September 15, 2026. The product, delivering 400 mg of VINIA and 6 mg of piceid resveratrol per chew, is intended to complement existing capsules and fit more daily habits, expanding consumer choice while reinforcing VINIA as a core commercial asset.
The launch aims to broaden VINIA’s addressable market by targeting consumers who prefer convenient, chewable supplements and by tapping into the rapidly growing global gummy and chewable segment. Management views the Daily Chews as both a driver of potential customer acquisition and retention and a practical showcase of BioHarvest’s botanical synthesis platform for prospective CDMO partners, illustrating how plant‑cell compositions can be translated into differentiated consumer products.
The most recent analyst rating on (BHST) stock is a Buy
with a $14.00 price target.
To see the full list of analyst forecasts on BioHarvest Sciences stock,
see the BHST Stock Forecast page.
Spark’s Take on BHST Stock
According to Spark, TipRanks’ AI Analyst, BHST is a Neutral.
The score is held down primarily by weak financial quality (ongoing losses and persistent cash burn) and a bearish technical setup (price below key moving averages and negative MACD). Offsetting factors include strong gross margins and revenue progress, plus earnings-call positives around improved cash and longer-term CDMO opportunity—though these are tempered by lowered 2026 guidance and continued EBITDA losses.
To see Spark’s full report on BHST stock,
click here.
More about BioHarvest Sciences
BioHarvest Sciences Inc., listed on Nasdaq, TASE and FSE, operates in the botanical synthesis and plant-based wellness sector. The company uses proprietary plant-cell biology and industrial-scale manufacturing to produce consistent, full‑spectrum plant compound compositions without growing the underlying plants, serving both its own consumer brands and contract development and manufacturing partners.
BioHarvest is increasingly positioning itself as a CDMO, helping partners develop, scale and manufacture valuable plant-based compositions across multiple industries. Its key proprietary asset is VINIA, a commercially established red‑grape cell composition and the first consumer product derived from its botanical synthesis platform, which also serves as a live proof of the technology’s commercial viability.
Average Trading Volume: 52,131
Technical Sentiment Signal: Buy
Current Market Cap: $41.94M